Felix S. Lichtenegger

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

Sascha Haubner, Fabiana Perna, Thomas Köhnke et al. · Leukemia · 2018 · 311 citations · Full text

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel et al. · Blood · 2013 · 199 citations

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

Felix S. Lichtenegger, Maurine Rothe, Frauke M. Schnorfeil et al. · Frontiers in Immunology · 2018 · 181 citations · Full text

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

Frauke M. Schnorfeil, Felix S. Lichtenegger, Katharina Emmerig et al. · Journal of Hematology & Oncology · 2015 · 144 citations · Full text

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <scp><i>PCM1</i>‐<i>JAK2</i></scp>, <scp><i>BCR‐JAK2</i></scp> and <scp><i>ETV6‐ABL1</i></scp> fusion genes

Juliana Schwaab, Nicole Naumann, Johannes Luebke et al. · American Journal of Hematology · 2020 · 71 citations · Full text

Myeloid Neoplasms, Mixed-phenotype Acute Leukemia, Tyrosine Kinase +21